“Genetic Polymorphism in CYP2D6 and Its Association With the Safety and Efficacy of Fluvoxamine in Patients With Major Depressive Disorder ”. Precision Medicine Communications 3, no. 1 (June 30, 2023): 43–49. Accessed May 8, 2026. https://rootspress.org/journals/index.php/PMC/article/view/301.